Skanska Secures Significant Contract for Biotechnology Facility
Skanska has recently announced an exciting development in its ongoing mission to enhance biotechnology research and innovation. The company has signed an important contract with the University of Virginia for the construction of a new state-of-the-art facility dedicated to biotechnology. This contract is valued at USD 66 million, or approximately SEK 690 million, and marks a significant milestone in Skanska's expanding portfolio in the biotechnology sector.
Details of the New Biotechnology Project
The upcoming building, known as the Paul and Diane Manning Institute of Biotechnology, will be situated within the Fontaine Research Park and is designed to be a pioneering space for research and innovation in the region. Once completed, this facility will encompass approximately 33,000 square meters (354,000 square feet) over five stories, creating an environment conducive to groundbreaking scientific endeavors.
A Hub for Collaborative Research
The institute will offer modular, multi-use laboratory space that promotes versatility and expansion for various research activities. Furthermore, it will provide enhanced core facilities, support spaces, and collaborative areas specifically designed to accommodate between 100 to 150 researchers and partner biotechnology firms. This collaborative setup aims to unite diverse talents and resources, accelerating advancements in biotechnology and related fields.
Project Timeline and Expectations
Construction for the Paul and Diane Manning Institute of Biotechnology commenced in December 2023, and the project is anticipated to reach completion by the fourth quarter of 2027. This timeline reflects Skanska's commitment to quality and meticulous project management, ensuring that the facility will meet the high standards expected in the biotechnology industry.
About Skanska
Skanska is renowned for its innovative approach to construction and development, especially in sectors that make a difference in people's lives. By focusing on sustainable practices and the latest technologies, Skanska is dedicated to building a better society and enhancing the communities it serves.
Contact Information
For more details regarding this groundbreaking project or media inquiries, you can reach the Communications Manager, Ashley Jeffery, at +1 813 459 3682. Additionally, Andreas Joons, Press Officer at Skanska Group, can be contacted at +46 76 870 75 51. For direct media inquiries, please call +46 (0)10 448 88 99.
Frequently Asked Questions
What is the purpose of the new biotechnology facility?
The facility will be dedicated to biotechnology research and collaboration, housing advanced laboratories and core research functions.
Who is partnering with Skanska on this project?
The University of Virginia is the primary partner for the construction of the Paul and Diane Manning Institute of Biotechnology.
What is the expected completion date for the facility?
The facility is expected to be completed by the fourth quarter of 2027.
How many researchers will the facility accommodate?
The institute is designed to support approximately 100 to 150 researchers and partnering biotechnology companies.
What is Skanska’s commitment to sustainability?
Skanska integrates sustainable practices in its construction projects, emphasizing environmental stewardship and community enhancement.
